Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mainz Biomed B.V. ( (MYNZ) ) has provided an announcement.
Mainz Biomed has successfully closed an $8 million follow-on offering, selling 1,367,521 units at $5.85 per unit. This financial boost is expected to support the company’s efforts in advancing their diagnostic products, potentially enhancing their position in the molecular genetics diagnostics industry.
More about Mainz Biomed B.V.
Mainz Biomed is a molecular genetics diagnostic company that specializes in developing market-ready diagnostic solutions for life-threatening conditions. Their flagship product is ColoAlert, a non-invasive early-detection test for colorectal cancer marketed in Europe. The company is also conducting an FDA clinical study for US approval and has a product candidate called PancAlert for pancreatic cancer screening.
YTD Price Performance: -88.45%
Average Trading Volume: 103,960
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.73M
For detailed information about MYNZ stock, go to TipRanks’ Stock Analysis page.
